阿立哌唑与氟哌啶醇治疗精神分裂症对照研究

目的评价阿立哌唑与氟哌啶醇治疗精神分裂症的疗效及安全性。方法阿立哌唑组35例，氟哌啶醇组36例，以阳性与阴性症状量表（PANSS）、临床疗效总评量表疾病严重程度（CGI—SI）、治疗中出现的症状量表（TESS）、锥体外系反应量表（RSESE）评定疗效及不良反应。疗程6周。结果两组疗效相仿。阿立哌唑组PANSS阴性症状因子减分在治疗后4周及6周显著优于氟哌啶醇组。阿立哌唑组不良反应显著较少。结论阿立哌唑是一种有效安全的抗精神病药。

Comparison study of aripiprazole and haloperidol in treatment of schizophrenia

Objective To compare the efficacy and safety of aripiprazole and haloperidol in treatment of schizophrenia. Methods Antipsychotic efficacy was assessed by positive and negative symptom scale （PANSS） and clinical global impressions-secerity of illness rating scale of illness rating scale（ CGL-SI）, antipsychotic side effect was assessed by treatment emergent symptom scale （TESS）, and rating scale for extrapyrarnidal side effects（RSESE） in 35 patients treated by aripiprazole（ aripiprazole group） and 36 patients treated by haloperidol （ hakioerudol group） for six weeks. Results The efficacy was similar in two groups. The reduction of total negative score in patients of aripiprazole group was significantly higher than that in haloperidol group after 4 and 6 weeks. Patients in aripiprazole group had significantly less side effects. Conclusion Aripiprazole is an effective and safe antipsychotic.